CIMETIDINE DOES NOT ALTER SPARFLOXACIN PHARMACOKINETICS

被引:0
|
作者
GRIES, JM
HONORATO, J
TABURET, AM
ALVAREZ, MP
SADABA, B
AZANZA, JR
SINGLAS, E
机构
[1] UNIV NAVARRA,E-31080 PAMPLONA,SPAIN
[2] HOP NECKER ENFANTS MALAD,F-75015 PARIS,FRANCE
关键词
SPARFLOXACIN; CIMETIDINE; PHARMACOKINETICS; DRUG INTERACTION;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The interaction between cimetidine and sparfloxacin was studied in 10 healthy volunteers who received a single oral dose of 400 mg sparfloxacin on the third day of an 8 day cimetidine (400 mg t.i.d.) or placebo randomly assigned treatment. No statistically significant differences were observed in the pharmacokinetic parameters (C-max - AUC - T-1/2 - urinary excretion and metabolic ratio) of sparfloxacin following the 2 treatment. Cimetidine does not affect absorption, metabolism or urinary excretion of sparfloxacin; consequently, patients exposed to this drug combination are not at risk.
引用
收藏
页码:585 / 587
页数:3
相关论文
共 50 条
  • [21] Pharmacokinetics of dolasetron with coadministration of cimetidine or rifampin in healthy subjects
    Dan C. Dimmitt
    Michael B. Cramer
    Anther Keung
    Thangam Arumugham
    Scott J. Weir
    Cancer Chemotherapy and Pharmacology, 1999, 43 : 126 - 132
  • [22] Pharmacokinetics of dolasetron with coadministration of cimetidine or rifampin in healthy subjects
    Dimmitt, DC
    Cramer, MB
    Keung, A
    Arumugham, T
    Weir, SJ
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1999, 43 (02) : 126 - 132
  • [23] Sparfloxacin pharmacokinetics in healthy volunteers: the influence of acidification and alkalinization
    Kamberi, M
    Kotegawa, T
    Tsutsumi, K
    Nakamura, K
    Nakano, S
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (08) : 633 - 637
  • [24] Does gender, food or grapefruit juice alter the pharmacokinetics of primaquine in healthy subjects?
    Cuong, Bui Tri
    Binh, Vu Quoc
    Dai, Bui
    Duy, Dinh Ngoc
    Lovell, Claire M.
    Rieckmann, Karl H.
    Edstein, Michael D.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 61 (06) : 682 - 689
  • [25] Mibefradil, a potent CYP3A inhibitor, does not alter pravastatin pharmacokinetics
    Becquemont, L
    Funck-Brentano, C
    Jaillon, P
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1999, 13 (02) : 232 - 236
  • [26] THE EFFECTS OF CIMETIDINE, RANITIDINE AND FAMOTIDINE ON THE SINGLE-DOSE PHARMACOKINETICS OF NAPROXEN AND ITS METABOLITES IN HUMANS
    VREE, TB
    VANDENBIGGELAARMARTEA, M
    VERWEYVANWISSEN, CPWGM
    VREE, ML
    GUELEN, PJM
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1993, 31 (12) : 597 - 601
  • [27] The influence of cimetidine on the pharmacokinetics of diltiazem and its main metabolite in rabbits
    Jun Shik Choi
    Jin Pil Burm
    Archives of Pharmacal Research, 2004, 27 : 254 - 258
  • [28] The influence of cimetidine on the pharmacokinetics of diltiazem and its main metabolite in rabbits
    Choi, JS
    Burm, JP
    ARCHIVES OF PHARMACAL RESEARCH, 2004, 27 (02) : 254 - 258
  • [29] The effects of ketoconazole and cimetidine on the pharmacokinetics of oral tramadol in greyhound dogs
    KuKanich, B.
    KuKanich, K.
    Black, J.
    JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2017, 40 (06) : e54 - e61
  • [30] Effcet of cimetidine and ranitidine on pharmacokinetics and pharmacodynamics of a single dose of dofetilide
    Abel, S
    Nichols, DJ
    Brearley, CJ
    Eve, MD
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 49 (01) : 64 - 71